NCT07444047 MRI-Based Lesion Differentiation in Older Patients With Multiple Sclerosis
| NCT ID | NCT07444047 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Oslo University Hospital |
| Condition | Multiple Sclerosis (MS) |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2026-05-11 |
| Primary Completion | 2030-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2026-05-11 with a primary completion date of 2030-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study investigates whether an advanced MRI technique called Quantitative Susceptibility Mapping (QSM) can improve the differentiation of white matter lesions in people aged 50-70 years with multiple sclerosis (MS). In older individuals with MS, white matter changes seen on MRI may be related to MS or to other types of white matter changes, most commonly age-related changes or chronic small vessel disease. These conditions can appear similar on conventional MRI scans, making interpretation challenging. Participants will undergo routine clinical MRI, including a short additional QSM sequence, as well as brief cognitive and physical assessments. A comparison group with cerebral small vessel disease will also be included. The goal of the study is to determine whether QSM can provide more precise lesion characterization and support more accurate clinical interpretation of MRI findings in older patients with MS.
Eligibility Criteria
Inclusion Criteria Multiple Sclerosis (MS) cohort (AgeMS): * Age 50-70 years * Clinically confirmed diagnosis of multiple sclerosis * Participation in the AgeMS study at Oslo University Hospital Inclusion Criteria Cerebral Small Vessel Disease (cSVD) control cohort: * Age 50-80 years * Radiological evidence of hypertensive small vessel disease on MRI * Good clinical recovery following transient ischemic attack (TIA), minor stroke, or stroke mimic diagnosis Exclusion Criteria Multiple Sclerosis (MS) cohort: * MRI contraindications * Severe psychiatric comorbidity * Major functional disability unrelated to MS or CSVD Exclusion Criteria Cerebral Small Vessel Disease (cSVD) control cohort: * MRI contraindications * Probable or definite cerebral amyloid angiopathy according to Boston criteria 2.0 * Genetic or inflammatory vasculopathies * Persistent neurological deficits * Severe psychiatric comorbidity * Major functional disability unrelated to CSVD
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07444047 clinical trial?
This trial is open to participants of all sexes, aged 50 Years or older, up to 80 Years, studying Multiple Sclerosis (MS). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07444047 currently recruiting?
Yes, NCT07444047 is actively recruiting participants. Contact the research team at anthbj@ous-hf.no for enrollment information.
Where is the NCT07444047 trial being conducted?
This trial is being conducted at Oslo, Norway.
Who is sponsoring the NCT07444047 clinical trial?
NCT07444047 is sponsored by Oslo University Hospital. The trial plans to enroll 1,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.